A Study in Advanced Solid Tumors

Exclusion Criteria

• •The participant has symptomatic brain or leptomeningeal metastasis.
• •The participant has not recovered from adverse events due to agents administered more than 4 weeks earlier. Neurotoxicity, if present, must have improved to Grade less than 2 per the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v 3.0.
• •The participant is receiving any other investigational agent(s).
• •The participant is receiving concurrent treatment with other anticancer therapy, including chemotherapy, immunotherapy, hormonal therapy,radiation therapy ( RT), chemoembolization, or targeted therapy. Participants receiving palliative radiation therapy to bony metastases prior to the first dose of study medication are eligible.
• •The participant is receiving therapy with immunosuppressive agents.
• •The participant has known drug or alcohol abuse.
• •The participant has uncontrolled hypertension defined as systolic blood pressure greater than or equal to 180 millimeters of mercury (mm Hg) or diastolic blood pressure greater than or equal to 130 mm Hg.
• •The participant has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab or carboplatin.
• •The participant has a medical or psychological condition that would not permit the participant to complete the study or sign informed consent.
• •The participant has clinically relevant coronary artery disease or history of myocardial infarction in the last 12 months or high risk of uncontrolled arrhythmia or uncontrolled cardiac insufficiency.
• •The participant, if female, is pregnant (confirmed by serum or urine beta-human chorionic gonadotropin \[β-HCG\] pregnancy test) or breastfeeding
• •The participant has had a known positive test result for the human immunodeficiency virus.
• •The participant has an active infection (requiring I.V antibiotics), including tuberculosis.